☰
×
News
Top 20
Insights
Insights+
ThoughtSpot
Interviews
Viewpoints
Exclusive
Spotlight
Events
Magazine
Bespoke
Newswire
x
Search
Search here
Search here
Subscribe Now
ovarian Cancer
PharmaShots Interview: Vigeo Therapeutics' Dr. Lou Vaickus and Dr. Jing Watnick Share Insights on VT1021 Data Presented at SITC 20...
January 15, 2021
AstraZeneca and MSD's Lynparza (olaparib) Receive EU's Approval as 1L Maintenance Treatment for HRD-Positive Advanced Ovarian Canc...
November 6, 2020
GSK's Zejula (niraparib) Receives EC's Approval as a Treatment in Advanced Ovarian Cancer
October 30, 2020
AstraZeneca and MSD Report Five Year Data of Lynparza in P-III SOLO-1 Study for 1L Maintenance Treatment in Patients with BRCA-Mut...
September 18, 2020
Roche Reports Results of Tecentriq in P-III IMagyn050 Study for Women with 1L Newly Diagnosed Advanced Stage Ovarian Cancer
July 13, 2020
GSK's Zejula (niraparib) Receives the US FDA's Approval as 1L Monotherapy Maintenance Treatment for Women with Advanced Ovarian Ca...
April 30, 2020
Load more...
Back to Home
Modal title
×
Modal body text goes here.